Residual human immunodeficiency virus type 1 RNA in lymphoid tissue of patients with sustained plasma RNA of <200 copies/mL

Journal of Infectious Diseases

Volumn 177, Issue 1, 1998, Pages 235-238

  Lafeuillade, Alain ^a   Chollet, Lionel ^b   Hittinger, Gilles ^b   Profizi, Nérina ^b   Costes, Olivier ^b   Poggi, Cécile ^b  

^a Hopital Chalucet Toulon   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL ARTICLE; DRUG EFFECT; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME; VIRUS DETECTION; VIRUS LOAD;

EID: 0031976036     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/517362     Document Type: Article

References (17)

1. Gulick R, Mellors J, Havlir D, et al. Potent and sustained antiretroviral activity of indinavir in combination with zidovudine and lamivudine [abstract LB7]. In: 3rd Conference on Retroviruses and Opportunistic Infections: program and abstracts (Washington, DC). Alexandria, VA: Infectious Diseases Society of America, 1996.
2. Perelson AS, Essunger P, Cao Y, et al. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 1997;387: 188-91.
3. Pantaleo G, Graziosi C, Demarest, et al. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature 1993;362:355-8.
4. Embretson J, Zupancic M, Ribas JL, et al. Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS. Nature 1993;362:359-62.
5. Lafeuillade A, Poggi C, Profizi N, Tamalet C, Costes O. Human immunodeficiency virus type 1 kinetics in lymph nodes compared with plasma. J Infect Dis 1996;174:404-7.
6. Cavert W, Notermans DW, Staskus K, et al. Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection. Science 1997;276:960-4.
7. Schockmel GA, Yerly S, Perrin L. Detection of low HIV-1 RNA levels in plasma. J Acquir Immune Defic Syndr Hum Retrovirol 1997;17: 179-83.
8. Mulder J, Resnick R, Saget B, et al. A rapid and simple method for extracting human immunodeficiency virus type 1 RNA from plasma: enhanced sensitivity. J Clin Microbiol 1997;35:1278-80.
9. Lafeuillade A, Poggi C, Tamalet C, Profizi N. HIV-1 dynamics in different lymphoid tissue compartments. J Infect Dis 1997;176:804-6.
10. Bürgisser P, Spertini F, Weyrich-Suter C, Pagani JL, Meylan PRA. Monitoring responses to antiretroviral treatment in human immunodeficiency virus type 1 (IHV-1)-infected patients by serial lymph node aspiration. J Infect Dis 1997;175:1202-5.
11. Wong JK, Gunthard HF, Havlir DV, et al. Reduction of HIV in blood and lymph nodes after potent antiretroviral therapy [abstract LB10]. In: 4th Conference on Retroviruses and Opportunistic Infections: program and abstracts (Washington, DC). Alexandria, VA: Infectious Diseases Society of America, 1997.
12. Pantaleo G. How immune-based interventions can change HIV therapy. Nature Med 1997;3:483-6.
13. Mascolini M. Nelfinavir is number 4 but should it bat cleanup, or lead off? J Intern Assoc Phys AIDS Care 1997;3:17-21.
14. Lange JMA. Current problems and the future of antiretroviral drug trials. Science 1997;276:548-50.
15. Cohen J. AIDS trials ethics questioned. Science 1997;276:520.
16. Feinberg M. Hidden dangers of incompletely suppressive antiretroviral therapy. Lancet 1997;349:1408-9.
17. Pantaleo G. Distribution of human immunodeficiency virus (HIV) in lymph nodes in different stages of HIV infection: implications for therapy and clinical monitoring. Antiviral Ther 1997;2(suppl 2): S7-S10.